Telomerase in cancer immunotherapy

Biochimica et Biophysica Acta - Reviews on Cancer

Volumn 1805, Issue 1, 2010, Pages 35-42

  Liu, Jun Ping ^a   Chen, Weisan ^b   Schwarer, Anthony P ^c   Li, He ^a  

^a MONASH UNIVERSITY   (Australia)

^b LUDWIG INSTITUTE FOR CANCER RESEARCH   (Australia)

^c ALFRED HOSPITAL   (Australia)

Author keywords

Cancer immunotherapy; hTERT; T cell; Telomerase; Tumor associated antigen

Indexed keywords

DNA VACCINE; HLA A3 ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; TELOMERASE REVERSE TRANSCRIPTASE;

ACUTE GRANULOCYTIC LEUKEMIA; ALLELE; ALLOGENEIC STEM CELL TRANSPLANTATION; ANTIGEN PRESENTATION; BREAST CANCER; CANCER CELL; CANCER IMMUNOTHERAPY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CYTOTOXIC T LYMPHOCYTE; GENETIC TRANSCRIPTION; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOLOGICAL TOLERANCE; LIVER CELL CARCINOMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW;

ANTIGENS, NEOPLASM; CANCER VACCINES; HUMANS; IMMUNOTHERAPY; NEOPLASMS; TELOMERASE;

EID: 75349112400     PISSN: 0304419X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbcan.2009.09.001     Document Type: Review

References (80)

1. Yamano T., Kaneda Y., Hiramatsu S.H., Huang S., Tran A.N., Giuliano A.E., and Hoon D.S. Immunity against breast cancer by TERT DNA vaccine primed with chemokine CCL21. Cancer Gene Ther. 14 (2007) 451-459
2. Shen X., Zhou J., Hathcock K.S., Robbins P., Powell Jr. D.J., Rosenberg S.A., and Hodes R.J. Persistence of tumor infiltrating lymphocytes in adoptive immunotherapy correlates with telomere length. J. Immunother. 30 (2007) 123-129
3. Bolonaki I., Kotsakis A., Papadimitraki E., Aggouraki D., Konsolakis G., Vagia A., Christophylakis C., Nikoloudi I., Magganas E., Galanis A., Cordopatis P., Kosmatopoulos K., Georgoulias V., and Mavroudis D. Vaccination of patients with advanced non-small-cell lung cancer with an optimized cryptic human telomerase reverse transcriptase peptide. J. Clin. Oncol. 25 (2007) 2727-2734
4. Domchek S.M., Recio A., Mick R., Clark C.E., Carpenter E.L., Fox K.R., DeMichele A., Schuchter L.M., Leibowitz M.S., Wexler M.H., Vance B.A., Beatty G.L., Veloso E., Feldman M.D., and Vonderheide R.H. Telomerase-specific T-cell immunity in breast cancer: effect of vaccination on tumor immunosurveillance. Cancer Res. 67 (2007) 10546-10555
5. Wenandy L., Sorensen R.B., Sengelov L., Svane I.M., thor Straten P., and Andersen M.H. The immunogenicity of the hTERT540-548 peptide in cancer. Clin. Cancer Res. 14 (2008) 4-7
6. Shay J.W., and Wright W.E. Telomerase therapeutics for cancer: challenges and new directions. Nat. Rev., Drug Discov. 5 (2006) 577-584
7. Harley C.B. Telomerase and cancer therapeutics. Nat. Rev., Cancer 8 (2008) 167-179
8. Kim J.H., Park S.M., Kang M.R., Oh S.Y., Lee T.H., Muller M.T., and Chung I.K. Ubiquitin ligase MKRN1 modulates telomere length homeostasis through a proteolysis of hTERT. Genes Dev. 19 (2005) 776-781
9. Pellicciotta I., Cortez-Gonzalez X., Sasik R., Reiter Y., Hardiman G., Langlade-Demoyen P., and Zanetti M. Presentation of telomerase reverse transcriptase, a self-tumor antigen, is down-regulated by histone deacetylase inhibition. Cancer Res. 68 (2008) 8085-8093
10. Vonderheide R.H., Hahn W.C., Schultze J.L., and Nadler L.M. The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes. Immunity 10 (1999) 673-679
11. Minev B., Hipp J., Firat H., Schmidt J.D., Langlade-Demoyen P., and Zanetti M. Cytotoxic T cell immunity against telomerase reverse transcriptase in humans. Proc. Natl. Acad. Sci. U. S. A. 97 (2000) 4796-4801
12. Lev A., Denkberg G., Cohen C.J., Tzukerman M., Skorecki K.L., Chames P., Hoogenboom H.R., and Reiter Y. Isolation and characterization of human recombinant antibodies endowed with the antigen-specific, major histocompatibility complex-restricted specificity of T cells directed toward the widely expressed tumor T-cell epitopes of the telomerase catalytic subunit. Cancer Res. 62 (2002) 3184-3194
13. Vonderheide R.H. Telomerase as a universal tumor-associated antigen for cancer immunotherapy. Oncogene 21 (2002) 674-679
14. Vonderheide R.H. Prospects and challenges of building a cancer vaccine targeting telomerase. Biochimie 90 (2008) 173-180
15. Schroers R., Huang X.F., Hammer J., Zhang J., and Chen S.Y. Identification of HLA DR7-restricted epitopes from human telomerase reverse transcriptase recognized by CD4+ T-helper cells. Cancer Res. 62 (2002) 2600-2605
16. Schroers R., Shen L., Rollins L., Rooney C.M., Slawin K., Sonderstrup G., Huang X.F., and Chen S.Y. Human telomerase reverse transcriptase-specific T-helper responses induced by promiscuous major histocompatibility complex class II-restricted epitopes. Clin. Cancer Res. 9 (2003) 4743-4755
17. Brunsvig P.F., Aamdal S., Gjertsen M.K., Kvalheim G., Markowski-Grimsrud C.J., Sve I., Dyrhaug M., Trachsel S., Moller M., Eriksen J.A., and Gaudernack G. Telomerase peptide vaccination: a phase I/II study in patients with non-small cell lung cancer. Cancer Immunol. Immunother. 55 (2006) 1553-1564
18. Vonderheide R.H., Anderson K.S., Hahn W.C., Butler M.O., Schultze J.L., and Nadler L.M. Characterization of HLA-A3-restricted cytotoxic T lymphocytes reactive against the widely expressed tumor antigen telomerase. Clin. Cancer Res. 7 (2001) 3343-3348
19. Amarnath S.M., Dyer C.E., Ramesh A., Iwuagwu O., Drew P.J., and Greenman J. In vitro quantification of the cytotoxic T lymphocyte response against human telomerase reverse transcriptase in breast cancer. Int. J. Oncol. 25 (2004) 211-217
20. Sievers E., Albers P., Schmidt-Wolf I.G., and Marten A. Telomerase pulsed dendritic cells for immunotherapy for renal cell carcinoma. J. Urol. 171 (2004) 114-119
21. Gannage M., Abel M., Michallet A.S., Delluc S., Lambert M., Giraudier S., Kratzer R., Niedermann G., Saveanu L., Guilhot F., Camoin L., Varet B., Buzyn A., and Caillat-Zucman S. Ex vivo characterization of multiepitopic tumor-specific CD8 T cells in patients with chronic myeloid leukemia: implications for vaccine development and adoptive cellular immunotherapy. J. Immunol. 174 (2005) 8210-8218
22. Ayyoub M., Migliaccio M., Guillaume P., Lienard D., Cerottini J.C., Romero P., Levy F., Speiser D.E., and Valmori D. Lack of tumor recognition by hTERT peptide 540-548-specific CD8(+) T cells from melanoma patients reveals inefficient antigen processing. Eur. J. Immunol. 31 (2001) 2642-2651
23. Hirano N., Butler M.O., Xia Z., Berezovskaya A., Murray A.P., Ansen S., Kojima S., and Nadler L.M. Identification of an immunogenic CD8+ T-cell epitope derived from gamma-globin, a putative tumor-associated antigen for juvenile myelomonocytic leukemia. Blood 108 (2006) 2662-2668
24. Filaci G., Fravega M., Setti M., Traverso P., Millo E., Fenoglio D., Negrini S., Ferrera F., Romagnoli A., Basso M., Contini P., Rizzi M., Ghio M., Benatti U., Damonte G., Ravetti J.L., Carmignani G., Zanetti M., and Indiveri F. Frequency of telomerase-specific CD8+ T lymphocytes in patients with cancer. Blood 107 (2006) 1505-1512
25. Speiser D.E., Cerottini J.C., and Romero P. Can hTERT peptide (540-548) -specific CD8 T cells recognize and kill tumor cells?. Cancer Immun. 2 (2002) 14
26. Rammensee H.G. Peptides made to order. Immunity 25 (2006) 693-695
27. Seifert U., Maranon C., Shmueli A., Desoutter J.F., Wesoloski L., Janek K., Henklein P., Diescher S., Andrieu M., de la Salle H., Weinschenk T., Schild H., Laderach D., Galy A., Haas G., Kloetzel P.M., Reiss Y., and Hosmalin A. An essential role for tripeptidyl peptidase in the generation of an MHC class I epitope. Nat. Immunol. 4 (2003) 375-379
28. Melief C.J. Mini-review: regulation of cytotoxic T lymphocyte responses by dendritic cells: peaceful coexistence of cross-priming and direct priming?. Eur. J. Immunol. 33 (2003) 2645-2654
29. Jonuleit H., Giesecke-Tuettenberg A., Tuting T., Thurner-Schuler B., Stuge T.B., Paragnik L., Kandemir A., Lee P.P., Schuler G., Knop J., and Enk A.H. A comparison of two types of dendritic cell as adjuvants for the induction of melanoma-specific T-cell responses in humans following intranodal injection. Int. J. Cancer 93 (2001) 243-251
30. de Vries I.J., Lesterhuis W.J., Scharenborg N.M., Engelen L.P., Ruiter D.J., Gerritsen M.J., Croockewit S., Britten C.M., Torensma R., Adema G.J., Figdor C.G., and Punt C.J. Maturation of dendritic cells is a prerequisite for inducing immune responses in advanced melanoma patients. Clin. Cancer Res. 9 (2003) 5091-5100
31. Dhodapkar M.V., Steinman R.M., Krasovsky J., Munz C., and Bhardwaj N. Antigen-specific inhibition of effector T cell function in humans after injection of immature dendritic cells. J. Exp. Med. 193 (2001) 233-238
32. Gilliet M., Kleinhans M., Lantelme E., Schadendorf D., Burg G., and Nestle F.O. Intranodal injection of semimature monocyte-derived dendritic cells induces T helper type 1 responses to protein neoantigen. Blood 102 (2003) 36-42
33. Nestle F.O., Alijagic S., Gilliet M., Sun Y., Grabbe S., Dummer R., Burg G., and Schadendorf D. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat. Med. 4 (1998) 328-332
34. Dupont J., Latouche J.B., Ma C., and Sadelain M. Artificial antigen-presenting cells transduced with telomerase efficiently expand epitope-specific, human leukocyte antigen-restricted cytotoxic T cells. Cancer Res. 65 (2005) 5417-5427
35. Li H., Katik I., and Liu J.P. Uses of telomerase peptides in anti-tumor immune therapy. Methods Mol. Biol. 405 (2008) 61-86
36. Vonderheide R.H., Domchek S.M., Schultze J.L., George D.J., Hoar K.M., Chen D.Y., Stephans K.F., Masutomi K., Loda M., Xia Z., Anderson K.S., Hahn W.C., and Nadler L.M. Vaccination of cancer patients against telomerase induces functional antitumor CD8+ T lymphocytes. Clin. Cancer Res. 10 (2004) 828-839
37. Dhodapkar M.V., Steinman R.M., Sapp M., Desai H., Fossella C., Krasovsky J., Donahoe S.M., Dunbar P.R., Cerundolo V., Nixon D.F., and Bhardwaj N. Rapid generation of broad T-cell immunity in humans after a single injection of mature dendritic cells. J. Clin. Invest. 104 (1999) 173-180
38. Nair S.K., Heiser A., Boczkowski D., Majumdar A., Naoe M., Lebkowski J.S., Vieweg J., and Gilboa E. Induction of cytotoxic T cell responses and tumor immunity against unrelated tumors using telomerase reverse transcriptase RNA transfected dendritic cells. Nat. Med. 6 (2000) 1011-1017
39. Heiser A., Maurice M.A., Yancey D.R., Coleman D.M., Dahm P., and Vieweg J. Human dendritic cells transfected with renal tumor RNA stimulate polyclonal T-cell responses against antigens expressed by primary and metastatic tumors. Cancer Res. 61 (2001) 3388-3393
40. Dudley M.E., Wunderlich J.R., Robbins P.F., Yang J.C., Hwu P., Schwartzentruber D.J., Topalian S.L., Sherry R., Restifo N.P., Hubicki A.M., Robinson M.R., Raffeld M., Duray P., Seipp C.A., Rogers-Freezer L., Morton K.E., Mavroukakis S.A., White D.E., and Rosenberg S.A. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 298 (2002) 850-854
41. Zhou J., Shen X., Huang J., Hodes R.J., Rosenberg S.A., and Robbins P.F. Telomere length of transferred lymphocytes correlates with in vivo persistence and tumor regression in melanoma patients receiving cell transfer therapy. J. Immunol. 175 (2005) 7046-7052
42. Robbins P.F., Dudley M.E., Wunderlich J., El-Gamil M., Li Y.F., Zhou J., Huang J., Powell Jr. D.J., and Rosenberg S.A. Cutting edge: persistence of rransferred lymphocyte clonotypes correlates with cancer regression in patients receiving cell transfer therapy. J. Immunol. 173 (2004) 7125-7130
43. Iwasaki T., Robertson N., Tsigani T., Finnon P., Scott D., Levine E., Badie C., and Bouffler S. Lymphocyte telomere length correlates with in vitro radiosensitivity in breast cancer cases but is not predictive of acute normal tissue reactions to radiotherapy. Int. J. Radiat. Biol. 84 (2008) 277-284
44. Reed J.R., Vukmanovic-Stejic M., Fletcher J.M., Soares M.V., Cook J.E., Orteu C.H., Jackson S.E., Birch K.E., Foster G.R., Salmon M., Beverley P.C., Rustin M.H., and Akbar A.N. Telomere erosion in memory T cells induced by telomerase inhibition at the site of antigenic challenge in vivo. J. Exp. Med. 199 (2004) 1433-1443
45. Akbar A.N., and Vukmanovic-Stejic M. Telomerase in T lymphocytes: use it and lose it?. J. Immunol. 178 (2007) 6689-6694
46. Choi J., Fauce S.R., and Effros R.B. Reduced telomerase activity in human T lymphocytes exposed to cortisol. Brain Behav. Immun. 22 (2008) 600-605
47. Roth A., Yssel H., Pene J., Chavez E.A., Schertzer M., Lansdorp P.M., Spits H., and Luiten R.M. Telomerase levels control the lifespan of human T lymphocytes. Blood 102 (2003) 849-857
48. Hooijberg E., Ruizendaal J.J., Snijders P.J., Kueter E.W., Walboomers J.M., and Spits H. Immortalization of human CD8+ T cell clones by ectopic expression of telomerase reverse transcriptase. J. Immunol. 165 (2000) 4239-4245
49. Andersen H., Barsov E.V., Trivett M.T., Trubey C.M., Giavedoni L.D., Lifson J.D., Ott D.E., and Ohlen C. Transduction with human telomerase reverse transcriptase immortalizes a rhesus macaque CD8+ T cell clone with maintenance of surface marker phenotype and function. AIDS Res. Hum. Retroviruses 23 (2007) 456-465
50. Migliaccio M., Amacker M., Just T., Reichenbach P., Valmori D., Cerottini J.C., Romero P., and Nabholz M. Ectopic human telomerase catalytic subunit expression maintains telomere length but is not sufficient for CD8+ T lymphocyte immortalization. J. Immunol. 165 (2000) 4978-4984
51. Schreurs M.W., Hermsen M.A., Geltink R.I., Scholten K.B., Brink A.A., Kueter E.W., Tijssen M., Meijer C.J., Ylstra B., Meijer G.A., and Hooijberg E. Genomic stability and functional activity may be lost in telomerase-transduced human CD8+ T lymphocytes. Blood 106 (2005) 2663-2670
52. Maecker B., von Bergwelt-Baildon M.S., Anderson K.S., Vonderheide R.H., Anderson K.C., Nadler L.M., and Schultze J.L. Rare naturally occurring immune responses to three epitopes from the widely expressed tumour antigens hTERT and CYP1B1 in multiple myeloma patients. Clin. Exp. Immunol. 141 (2005) 558-562
53. Parkhurst M.R., Riley J.P., Igarashi T., Li Y., Robbins P.F., and Rosenberg S.A. Immunization of patients with the hTERT:540-548 peptide induces peptide-reactive T lymphocytes that do not recognize tumors endogenously expressing telomerase. Clin. Cancer Res. 10 (2004) 4688-4698
54. Purbhoo M.A., Li Y., Sutton D.H., Brewer J.E., Gostick E., Bossi G., Laugel B., Moysey R., Baston E., Liddy N., Cameron B., Bennett A.D., Ashfield R., Milicic A., Price D.A., Classon B.J., Sewell A.K., Jakobsen B.K., and The H. A*0201-restricted hTERT(540-548) peptide is not detected on tumor cells by a CTL clone or a high-affinity T-cell receptor. Mol. Cancer Ther. 6 (2007) 2081-2091
55. Arai J., Yasukawa M., Ohminami H., Kakimoto M., Hasegawa A., and Fujita S. Identification of human telomerase reverse transcriptase-derived peptides that induce HLA-A24-restricted antileukemia cytotoxic T lymphocytes. Blood 97 (2001) 2903-2907
56. Mizukoshi E., Nakamoto Y., Marukawa Y., Arai K., Yamashita T., Tsuji H., Kuzushima K., Takiguchi M., and Kaneko S. Cytotoxic T cell responses to human telomerase reverse transcriptase in patients with hepatocellular carcinoma. Hepatology 43 (2006) 1284-1294
57. Adotevi O., Mollier K., Neuveut C., Cardinaud S., Boulanger E., Mignen B., Fridman W.H., Zanetti M., Charneau P., Tartour E., Lemonnier F., and Langlade-Demoyen P. Immunogenic HLA-B*0702-restricted epitopes derived from human telomerase reverse transcriptase that elicit antitumor cytotoxic T-cell responses. Clin. Cancer Res. 12 (2006) 3158-3167
58. Cortez-Gonzalez X., Sidney J., Adotevi O., Sette A., Millard F., Lemonnier F., Langlade-Demoyen P., and Zanetti M. Immunogenic HLA-B7-restricted peptides of hTRT. Int. Immunol. 18 (2006) 1707-1718
59. Liu G.Y., Fairchild P.J., Smith R.M., Prowle J.R., Kioussis D., and Wraith D.C. Low avidity recognition of self-antigen by T cells permits escape from central tolerance. Immunity 3 (1995) 407-415
60. Harrington C.J., Paez A., Hunkapiller T., Mannikko V., Brabb T., Ahearn M., Beeson C., and Goverman J. Differential tolerance is induced in T cells recognizing distinct epitopes of myelin basic protein. Immunity 8 (1998) 571-580
61. Scardino A., Gross D.A., Alves P., Schultze J.L., Graff-Dubois S., Faure O., Tourdot S., Chouaib S., Nadler L.M., Lemonnier F.A., Vonderheide R.H., Cardoso A.A., and Kosmatopoulos K. HER-2/neu and hTERT cryptic epitopes as novel targets for broad spectrum tumor immunotherapy. J. Immunol. 168 (2002) 5900-5906
62. Hernandez J., Garcia-Pons F., Lone Y.C., Firat H., Schmidt J.D., Langlade-Demoyen P., and Zanetti M. Identification of a human telomerase reverse transcriptase peptide of low affinity for HLA A2.1 that induces cytotoxic T lymphocytes and mediates lysis of tumor cells. Proc. Natl. Acad. Sci. U. S. A. 99 (2002) 12275-12280
63. Tourdot S., Scardino A., Saloustrou E., Gross D.A., Pascolo S., Cordopatis P., Lemonnier F.A., and Kosmatopoulos K. A general strategy to enhance immunogenicity of low-affinity HLA-A2. 1-associated peptides: implication in the identification of cryptic tumor epitopes. Eur. J. Immunol. 30 (2000) 3411-3421
64. Krausa P., Brywka III M., Savage D., Hui K.M., Bunce M., Ngai J.L., Teo D.L., Ong Y.W., Barouch D., Allsop C.E., et al. Genetic polymorphism within HLA-A*02: significant allelic variation revealed in different populations. Tissue Antigens 45 (1995) 223-231
65. Slansky J.E., Rattis F.M., Boyd L.F., Fahmy T., Jaffee E.M., Schneck J.P., Margulies D.H., and Pardoll D.M. Enhanced antigen-specific antitumor immunity with altered peptide ligands that stabilize the MHC-peptide-TCR complex. Immunity 13 (2000) 529-538
66. Mavroudis D., Bolonakis I., Cornet S., Myllaki G., Kanellou P., Kotsakis A., Galanis A., Nikoloudi I., Spyropoulou M., Menez J., Miconnet I., Niniraki M., Cordopatis P., Kosmatopoulos K., and Georgoulias V. A phase I study of the optimized cryptic peptide TERT(572y) in patients with advanced malignancies. Oncology 70 (2006) 306-314
67. Thorn M., Wang M., Kloverpris H., Schmidt E.G., Fomsgaard A., Wenandy L., Berntsen A., Brunak S., Buus S., and Claesson M.H. Identification of a new hTERT-derived HLA-A*0201 restricted, naturally processed CTL epitope. Cancer Immunol. Immunother. 56 (2007) 1755-1763
68. Pardoll D.M., and Topalian S.L. The role of CD4+ T cell responses in antitumor immunity. Curr. Opin. Immunol. 10 (1998) 588-594
69. Rosenberg S.A. Progress in human tumour immunology and immunotherapy. Nature 411 (2001) 380-384
70. Ostrand-Rosenberg S. CD4+ T lymphocytes: a critical component of antitumor immunity. Cancer Invest. 23 (2005) 413-419
71. Kokhaei P., Palma M., Hansson L., Osterborg A., Mellstedt H., and Choudhury A. Telomerase (hTERT 611-626) serves as a tumor antigen in B-cell chronic lymphocytic leukemia and generates spontaneously antileukemic, cytotoxic T cells. Exp. Hematol. 35 (2007) 297-304
72. Chen Q., Jackson H., Parente P., Luke T., Rizkalla M., Tai T.Y., Zhu H.C., Mifsud N.A., Dimopoulos N., Masterman K.A., Hopkins W., Goldie H., Maraskovsky E., Green S., Miloradovic L., McCluskey J., Old L.J., Davis I.D., Cebon J., and Chen W. Immunodominant CD4+ responses identified in a patient vaccinated with full-length NY-ESO-1 formulated with ISCOMATRIX adjuvant. Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 9363-9368
73. Bernhardt S.L., Gjertsen M.K., Trachsel S., Moller M., Eriksen J.A., Meo M., Buanes T., and Gaudernack G. Telomerase peptide vaccination of patients with non-resectable pancreatic cancer: A dose escalating phase I/II study. Br. J. Cancer 95 (2006) 1474-1482
74. Schreurs M.W., Kueter E.W., Scholten K.B., Kramer D., Meijer C.J., and Hooijberg E. Identification of a potential human telomerase reverse transcriptase-derived, HLA-A1-restricted cytotoxic T-lymphocyte epitope. Cancer Immunol. Immunother. 54 (2005) 703-712
75. Lin X., Zhou C., Wang S., Wang D., Ma W., Liang X., Lin C., Wang Z., Li J., Guo S., Zhang Y., and Zhang S. Enhanced antitumor effect against human telomerase reverse transcriptase (hTERT) by vaccination with chemotactic-hTERT gene-modified tumor cell and the combination with anti-4-1BB monoclonal antibodies. Int. J. Cancer 119 (2006) 1886-1896
76. Kim C.H., Yoon J.S., Sohn H.J., Kim C.K., Paik S.Y., Hong Y.K., and Kim T.G. Direct vaccination with pseudotype baculovirus expressing murine telomerase induces anti-tumor immunity comparable with RNA-electroporated dendritic cells in a murine glioma model. Cancer Lett. 250 (2007) 276-283
77. Cornet S., Menez-Jamet J., Lemonnier F., Kosmatopoulos K., and Miconnet I. CpG oligodeoxynucleotides activate dendritic cells in vivo and induce a functional and protective vaccine immunity against a TERT derived modified cryptic MHC class I-restricted epitope. Vaccine 24 (2006) 1880-1888
78. Su Z., Vieweg J., Weizer A.Z., Dahm P., Yancey D., Turaga V., Higgins J., Boczkowski D., Gilboa E., and Dannull J. Enhanced induction of telomerase-specific CD4(+) T cells using dendritic cells transfected with RNA encoding a chimeric gene product. Cancer Res. 62 (2002) 5041-5048
79. Williams M.A., and Bevan M.J. Effector and memory CTL differentiation. Annu. Rev. Immunol. 25 (2007) 171-192
80. Cassar L., Li H., Pinto A.R., Nicholls C., Bayne S., and Liu J.-P. Bone morphogenetic protein-7 inhibits telomerase activity, telomere maintenance, and cervical tumor growth. Cancer Res. 68 (2008) 9157-9166